| Literature DB >> 10704442 |
S R Cronin1, A Khoury, D K Ferry, R Y Hampton.
Abstract
The integral ER membrane protein HMG-CoA reductase (HMGR) is a key enzyme of the mevalonate pathway from which sterols and other essential molecules are produced. HMGR degradation occurs in the ER and is regulated by mevalonate-derived signals. Little is known about the mechanisms responsible for regulating HMGR degradation. The yeast Hmg2p isozyme of HMGR undergoes regulated degradation in a manner very similar to mammalian HMGR, allowing us to isolate mutants deficient in regulating Hmg2p stability. We call these mutants cod mutants for the control of HMG-CoA reductase degradation. With this screen, we have identified the first gene of this class, COD1, which encodes a P-type ATPase and is identical to SPF1. Our data suggested that Cod1p is a calcium transporter required for regulating Hmg2p degradation. This role for Cod1p is distinctly different from that of the well-characterized Ca(2+) P-type ATPase Pmr1p which is neither required for Hmg2p degradation nor its control. The identification of Cod1p is especially intriguing in light of the role Ca(2+) plays in the regulated degradation of mammalian HMGR.Entities:
Mesh:
Substances:
Year: 2000 PMID: 10704442 PMCID: PMC2174543 DOI: 10.1083/jcb.148.5.915
Source DB: PubMed Journal: J Cell Biol ISSN: 0021-9525 Impact factor: 10.539
Figure 1Regulation of Hmg2p degradation by the mevalonate pathway. (A) Increased production of FPP promotes Hmg2p degradation. Relevant pathway intermediates are shown. Drugs are shown above the enzymatic step that is inhibited (L659, L659,699; LOVA, lovastatin; ZA, zaragozic acid; Ro, Ro48-8071). Dotted arrows indicate multi-enzyme steps. (B) A model for genes that control of Hmg2p degradation. Entry of Hmg2p into the HRD-encoded ER degradation pathway is controlled by COD genes in response to an FPP-derived signal.
Yeast Strains
| Strain | Genotype |
|---|---|
| RHY468 | MAT |
| RHY541 | MAT |
| RHY542 | MATa hmg2::HIS3::1mycHMG2 ura3-52::URA3::HMG2::GFP LEU2 |
| RHY555 | MATa hmg2::HIS3 ura3-52::6MYC HMG2 hrd1-1 LEU2 |
| RHY658 | MAT |
| RHY660 | MATa hmg2::HIS3::1mycHMG2 ura3-52::URA3::HMG2::GFP LEU2 cod1-1 |
| RHY791 | MAT |
| RHY792 | MATa hmg2::HIS3::1mycHMG2 ura3-52::URA3::HMG2::GFP |
| RHY811 | MAT |
| RHY812 | MATa hmg2::HIS3::1mycHMG2 ura3-52::URA3::HMG2::GFP cod1-1 |
| RHY871 | MAT |
| RHY872 | MATa hmg2::HIS3::1mycHMG2 ura3-52:LEU2::HMG2::GFP |
| RHY880 |
|
| RHY910 | MAT |
| RHY911 | MATa hmg2::HIS3::1mycHMG2 ura3-52:LEU2::HMG2::GFP cod1-1 |
| RHY1056 |
|
| RHY1076 |
|
| RHY1077 |
|
| RHY1127 |
|
| RHY1128 |
|
| RHY1202 |
|
| RHY1203 | MAT |
| RHY1205 | MAT |
| RHY1473 | MAT |
| RHY1475 | MAT |
| RHY1882 | MAT |
| RHY1883 |
|
| RHY2201 | MAT |
| RHY2202 |
|
| RHY2203 |
|
| RHY2204 |
|
Figure 2cod1-1 prevented regulation of Hmg2p-GFP level and caused lovastatin hypersensitivity. (A) Regulation of Hmg2p-GFP stability in wild-type or cod1-1 cells. Early log phase cultures were allowed to grow for 4 h in the presence or absence of 25 μg/ml lovastatin (LOVA). Each panel shows equivalent numbers of cells, photographed with identical optical settings. (B) Regulation of Hmg2p-GFP level examined by flow microfluorimetry. Cultures of wild-type or cod1-1 cells were grown for 4 h without drugs or in the presence of lovastatin or zaragozic acid (ZA) as indicated and then subjected to flow microfluorimetry. Each histogram represents 10,000 cells. (C) Growth arrest of wild-type and cod1-1 cells by mevalonate pathway inhibitors. Low density (OD600 < 0.01) cultures were allowed to grow for 2.5 d in the indicated concentrations of lovastatin or L659,699. Final OD600 readings were taken for each concentration and plotted as percent of the appropriate untreated culture. Representative experiments are shown.
Figure 3cod1-1 disrupted regulation of 1myc-Hmg2p degradation. Wild-type or cod1-1 cells were examined for degradation of 1myc-Hmg2p by addition of cycloheximide at time 0, followed by lysis at the indicated time (0 or 4 hours), and anti-myc immunoblotting. Lovastatin (L) was added to the indicated samples at the same time as cycloheximide.
Figure 4Ubiquitination of Hmg2p was unregulated in cod1-1 cells. Wild-type or cod1-1 cells expressing HA-tagged ubiquitin were grown in the presence or absence of the indicated drugs. L659,699 (L6) was added 30 min before lysis and zaragozic acid (ZA) was added 10 min before lysis. The cultures were lysed, Hmg2p was immunoprecipitated with antibodies against Hmg2p and then immunoblotted following SDS-PAGE. Ubiquitinated Hmg2p was detected by anti-HA immunoblotting, and total Hmg2p was detected by anti-myc immunoblotting.
Figure 5Hmg2p in cod1-1 was stabilized by ER degradation mutants. (A) Hmg2p-GFP fluorescence of wild-type or mutant cells was examined by fluorescence microscopy. Cells in the top row of panels are wild-type for COD1 and cells in the bottom row have the cod1-1 mutation. Cells in the middle and right columns have ubc7Δ or hrd1Δ null alleles, respectively. Equivalent numbers of cells were photographed in each panel using identical settings. (B) Degradation of Hmg2p-GFP was examined by flow microfluorimetry in wild-type or cod1-1 cells with or without ubc7Δ or hrd1Δ as labeled. Cycloheximide (CHX) was added to the indicated cultures 4 h before analysis. (C) 1myc-Hmg2p degradation in wild-type, cod1-1, ubc7Δ, and cod1-1/ubc7Δ cells was assayed by cycloheximide chase. After addition of cycloheximide samples were lysed at 0 or 4 h followed by SDS-PAGE and immunoblotting of the lysates. Lovastatin (L) was added to the indicated samples at the same time as cycloheximide.
Figure 6The stability of other ER membrane proteins in Cod− cells. (A) Wild-type and cod1-1 cells expressing either Hmg2p-GFP or Hmg1p-GFP were assayed by flow microfluorimetry for loss of fluorescence after 4-h incubation in the presence or absence of cycloheximide (CHX). (B) The stability of 6myc-Hmg2p-GFP in wild-type and cod1Δ cells was assayed by cycloheximide chase. After addition of cycloheximide samples were lysed at various times followed by SDS-PAGE and immunoblotting of the lysates. (C) The K6R mutation enhances Hmg2p-GFP stability in cod1-1. Wild-type and cod1-1 cells expressing either Hmg2p-GFP or the K6R variant of Hmg2p-GFP were assayed by flow microfluorimetry for loss of fluorescence after 4-h incubation in the presence or absence of cycloheximide (CHX).
Figure 8CaCl2 restored control of degradation to cod1-1. Wild-type or cod1Δ cells were grown overnight in the presence or absence of 200 mM CaCl2. Lovastatin (lova) was added to the indicated cultures 4 h before analysis by flow microfluorimetry.
Figure 9EGTA blunted regulation of Hmg2p-GFP levels in a Ca2+-dependent manner. Cells expressing Hmg2p-GFP were assayed for regulation of fluorescence after overnight growth in the presence or absence 780 μM EGTA. Lovastatin (lova), zaragozic acid (ZA), and/or CaCl2 were added 4 h before analysis.